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Abstract. Frailty, a critical intermediate status of the aging process that is at increased risk for negative health-related events,
includes physical, cognitive, and psychosocial domains or phenotypes. Cognitive frailty is a condition recently defined by
operationalized criteria describing coexisting physical frailty and mild cognitive impairment (MCI), with two proposed
subtypes: potentially reversible cognitive frailty (physical frailty/MCI) and reversible cognitive frailty (physical frailty/pre-
MCI subjective cognitive decline). In the present article, we reviewed the framework for the definition, different models,
and the current epidemiology of cognitive frailty, also describing neurobiological mechanisms, and exploring the possible
prevention of the cognitive frailty progression. Several studies suggested a relevant heterogeneity with prevalence estimates
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ranging 1.0–22.0% (10.7–22.0% in clinical-based settings and 1.0–4.4% in population-based settings). Cross-sectional and
longitudinal population-based studies showed that different cognitive frailty models may be associated with increased risk
of functional disability, worsened quality of life, hospitalization, mortality, incidence of dementia, vascular dementia, and
neurocognitive disorders. The operationalization of clinical constructs based on cognitive impairment related to physical
causes (physical frailty, motor function decline, or other physical factors) appears to be interesting for dementia secondary
prevention given the increased risk for progression to dementia of these clinical entities. Multidomain interventions have
the potential to be effective in preventing cognitive frailty. In the near future, we need to establish more reliable clinical and
research criteria, using different operational definitions for frailty and cognitive impairment, and useful clinical, biological,
and imaging markers to implement intervention programs targeted to improve frailty, so preventing also late-life cognitive
disorders.
Keywords: Alzheimer’s disease, biomarkers, dementia, frailty, lifestyle, mild cognitive impairment, nutrition, prevention,
subjective cognitive decline, vascular dementia
INTRODUCTION
Chronic diseases accelerate aging, thereby dimin-
ishing the body’s adaptation via the relevant stress
responses. In older age, multiple subclinical and age-
related comorbidities and the occurrence of stressors
(i.e., illness, injury, psychosocial stress) may exacer-
bate functional decline in the physiological reserves
of several systems, which would then result in a
homeostatic imbalance or frailty. In 1965, Bernard
Isaacs coined the term “geriatric giants”, includ-
ing in this definition syndromes such as immobility,
instability and falls, incontinence (urinary and fecal),
and intellectual impairment (delirium and dementia)
[1]. Over the subsequent five decades, the modern
“geriatric giants” has evolved encompassing the four
new syndromes of frailty, sarcopenia, the anorexia
of aging, and cognitive impairment [2]. The term
‘frailty’ has been used scientifically since at least
1979, when Vaupel and colleagues employed it to
describe variability in life expectancy [3]. In geri-
atric medicine, frailty was a condition at higher
risk for adverse health-related outcomes, includ-
ing falls, disability, hospitalizations, and mortality.
Therefore, frailty is a critical intermediate status of
the aging process and the development of frailty
is a novel perspective to health and wellness that
gained considerable attention as a stronger indi-
cator than chronologic aging of biological aging
and survival [4, 5]. Therefore, frailty is a modern
geriatric giant and the recent Asia-Pacific Clinical
Practice Guidelines for the Management of Frailty
[6] and the International Association of Gerontol-
ogy and Geriatrics (IAGG) Frailty Consensus [4]
defined frailty as a reduced strength and physiologic
malfunctioning that increases an individual’s suscep-
tibility to increased dependency, vulnerability, and
death. After more than twenty years of intensive
clinical research, no accepted reference standard,
universal criteria, or consensus operational defini-
tion has been reached nor have definitive assessment
tools or biological markers been established to iden-
tify frailty, and extensive international efforts are
underway to identify the means of optimal mea-
surement. Among over forty operational definitions
proposed, three major approaches to defining frailty
exist. The first was the concept of physical frailty
phenotype, probably the most popular model of this
condition and offering an operational definition based
on an assumed state of negative energy balance, sar-
copenia, diminished strength, and low tolerance for
exertion. This phenotype or biological model was
originally operationalized using the Cardiovascular
Health Study (CHS) database, using five practically
measurable items: exhaustion, involuntary weight
loss, weak grip strength, slow walking speed, and
low energy expenditure, and the number of positive
items defined the individual as frail (≥3), prefrail
(1–2), and robust (none) [7]. Cognition and mood
were excluded. An alternative and potentially com-
plementary definition of frailty is the so-called deficit
accumulation model, incorporating a large number
of candidate factors ranging from disease states,
symptoms, signs, to abnormal laboratory values.
When combined and divided by the total number of
deficits, these yield a frailty index [8, 9]. Differently
from the frailty phenotype, the deficit accumulation
model of frailty is based on the results of a previ-
ous comprehensive geriatric assessment (CGA) [10],
defining a status of biological aging and includ-
ing cognitive, emotional, motivational, and social
characteristics given the multidimensional and multi-
system nature of biological changes underpinning the
frail condition. The third approach to frailty deserv-
ing special attention is the biopsychosocial model
[11, 12], mixing physical and psychosocial domains,
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and expanding the construct of frailty toward social
sciences.
DIFFERENT FRAILTY PHENOTYPES
Frailty might be a con sequence of increasing
entropy and gradual disorganization of the body, in
a way that is similar to dementia [13]; therefore, it
may be difficult to understand when frailty from a
risk-state becomes a true pathological state. Frailty is
currently considered as “primary” or “pre-clinical”
when the state is not associated directly with a spe-
cific disease, or when there is no substantial disability
[14]. In this context, the physical phenotype seems
more appropriate to define primary frailty [7]. In con-
trast, frailty is considered “secondary” or “clinical”
when it is associated with known comorbidity such
as dementia or overt cardiovascular disease and/or
disability [15]. Therefore, this condition appears to
be better defined with the model linking frailty to
the accumulation of deficits [8, 9]. While most of
the available definitions have privileged the physical
dimension of frailty, other factors such as nutrition
[16], depression [17], and cognition [18] may also
influence the status of this syndrome in older age.
The multidimensional nature of the deficit accumula-
tion model and the biopsychosocial model prompted
an approach to frailty based on different pathogene-
ses, and this heterogeneous clinical syndrome may
include physical, cognitive, social, and psychologi-
cal domains [2]. Therefore, the principal phenotypes
are physical frailty [7], cognitive frailty [19], social
frailty [20], and psychological frailty [21], this last
encompassing motivational and mood components,
i.e., the recently proposed depressive frail phenotype
[22]. Among these phenotypes, social frailty is the
most unexplored concept, while the identification of
social frailty models could be a further step for a more
global appreciation of frailty, taking into account the
role played by the socioeconomic context in deter-
mining the vulnerability status in older age. Social
frailty can be defined as a continuum of being at risk
of losing, or having lost, social and general resources,
activities, or abilities that are important for fulfilling
one or more basic social needs during the lifespan
[20]. In population-based studies, social frailty has
been operationalized with single questions or items
from functional and depressive symptom scales or
health checklists [23, 24]. In this setting, social frailty
status may be predictive of mortality [23], disability
[24, 25], and cognitive outcomes [24] in older age.
Psychological frailty, encompassing the concepts of
mood and motivational frailty, also suggests a parallel
to physical frailty in the domains of mood, a relatively
persistent state of emotion such as depression, fear,
anxiety, or anger, and motivation, the drive toward a
goal, or lack thereof (apathy), that is linked to mood
but can be largely independent of it as is noted, for
example, in nondepressed individuals with demen-
tia [20]. In particular, depression and physical frailty
share several clinical characteristics such as loss of
energy, fatigability, poor sleep, and reduced interest
[20]. Moreover, there was a bidirectional associa-
tion between depression and physical frailty in later
life [17], although have not explored the possibility
of the existence of a primary, intrinsic vulnerabil-
ity to emotional stressors with age that might signal
mood frailty, a possible precursor to depression and
its negative health outcomes [20]. Very recently, it
was proposed a depressive frail phenotype as a high-
risk morbidity and mortality syndrome of later life,
reassembling the confluence between depression and
frailty [22]. This model hypothesized that charac-
teristics of frailty in adults with late-life depression
may represent the clinical manifestation of greater
biological aging, exposing elders to deleterious tra-
jectories [22]. Finally, notwithstanding the clinical or
biological characterization of these different frailty
phenotypes, it remains unclear whether people who
suffer from multiple frailty phenotypes are at greater
risk for negative outcomes of frailty. As deficits in
the physical dimension are particularly known to be
important predictors for adverse health-related out-
comes, this phenotype may be taken as reference
[26]. However, whether physically frail older people
are more at risk for developing adverse outcomes if
they also suffer from cognitive, social, or psycholog-
ical frailty remains an open issue [27]. Among these
different phenotypes, cognitive frailty is increasingly
recognized as a fundamental determinant of the indi-
vidual’s vulnerability and resilience to stressors [28].
The present narrative review article aimed to refine
the framework for the definition, different models,
relevant screening and diagnostic tools, biomarkers,
and the current epidemiology of cognitive frailty,
also describing neurobiological mechanisms under-
lying this novel construct, and exploring the possible
prevention of the cognitive frailty progression.
COGNITIVE FRAILTY: AN EMERGING
CONCEPT
A recent and growing body of epidemiological evi-
dence suggested that frailty may increase the risk of
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future cognitive decline and that cognitive impair-
ment may increase the risk of frailty suggesting that
cognition and frailty may interact in advancing aging
[18, 29, 30]. Several studies examined frailty and
cognitive impairment as both antecedents and out-
comes [31]. The mutual influences between frailty
and impaired cognition have been discussed, includ-
ing the proposed construct of cognitive frailty. In fact,
while physical frailty phenotype is a widely recog-
nized problem in older age, only in recent years has
the term cognitive frailty emerged in the literature.
In 2001, this term was incidentally used by Paganini-
Hill and colleagues in a study on Clock Drawing Test
(CDT) performance and its association with potential
protective and risk factors for Alzheimer’s disease
(AD) in an older cohort [32]. In 2004, the term cog-
nitive frailty has been used as a general descriptor
for cognitive impairment occurring as people reach
advanced age, or to refer to cognitive disturbances
or predementia occurring in association with other
medical conditions [33]. However, only in 2006, cog-
nitive frailty was used as a clinical label to indicate
a particular state of cognitive vulnerability in mild
cognitive impairment (MCI) and other similar clini-
cal entities exposed to vascular risk factors and with
a subsequent increased progression to dementia, par-
ticularly vascular dementia (VaD) [34]. In 2013, a
consensus on the definition of cognitive frailty was
reached by an international consensus group from
the International Academy of Nutrition and Aging
(IANA) and the IAGG [35]. The proposed diagnostic
criteria for this novel and heterogeneous clinical age-
related condition included the simultaneous presence
of physical frailty operationalized with the CHS phe-
notypic/biological model and cognitive impairment
diagnosed with a Clinical Dementia Rating (CDR)
scale of 0.5 (i.e., questionable dementia, a stage of
the dementia continuum similar to MCI) without a
concurrent diagnosis of AD or other dementias [35]
(Table 1). Therefore, cognitive frailty is held to be
a combination of MCI and physical frailty, which is
defined by the five classical features of CHS, three of
which (i.e., reduced physical activity, motor slowing,
weight loss) are known to be risk factors for dementia
[35].
The potential for reversibility of different
cognitive frailty models
Among frailty phenotypes, cognitive frailty has
been proposed as a clinical entity with cogni-
tive impairment related to physical causes, with a
potential reversibility, and as an important target
of secondary intervention in early or asymptomatic
stage of dementia [36]. In 2015, the first systematic
review on this intriguing topic suggested that frailty
indexes based on a deficit accumulation model were
associated in hospital- and population-based studies
with late-life cognitive impairment and decline, inci-
dent dementia, and AD [37]. Furthermore, physical
frailty models may also be associated with late-life
cognitive impairment and decline, incident AD and
MCI, VaD, non-AD dementias, and AD pathology in
older persons with and without dementia, so giving
support to identify cognitive frailty as a new clinical
condition [37]. Recently, a meta-analysis suggested
that the frailty was a significant predictor of AD, VaD,
and all dementia among community-dwelling older
people, with frail women at higher risk of incident
AD than frail men [38].
The potential for reversibility of frailty and its
different phenotypes suggests that these clinical con-
structs may be important secondary targets for the
prevention of dependency and other negative out-
comes in older age [19]. More recently, in an attempt
to refine the framework for the definition and poten-
tial mechanisms of cognitive frailty, two subtypes
for this clinical construct were proposed: “poten-
tially reversible” cognitive frailty and “reversible”
cognitive frailty [19, 39] (Table 1). The physi-
cal factors should be physical prefrailty and frailty
for both the subtypes. The cognitive impairment
of potentially reversible cognitive frailty should be
MCI (CDR = 0.5), while the cognitive impairment of
reversible cognitive frailty should be pre-MCI subjec-
tive cognitive decline (SCD) (CDR = 0), as recently
formulated by the Subjective Cognitive Decline Ini-
tiative (SCD-I) Working Group that proposed a basic
conceptual framework for the study of the common
concepts of SCD, pre-MCI SCD, and SCD in preclin-
ical AD [40].
Screening and diagnostic tools defining cognitive
frailty
The current working definitions of cognitive frailty
[20, 34, 38] may provide a valuable starting point
for the development of a coherent operational def-
inition and for future studies of cognitive frailty.
While the physical factors of cognitive frailty were
diagnosed with the physical frailty model opera-
tionalized with the CHS criteria, the cognitive pattern
of this clinical construct was not clearly character-
ized. The studies published so far mostly adopted
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Table 1
Different operational models of cognitive frailty for older individuals without Alzheimer’s disease
or other forms of dementia







CHS physical frailty items
Exhaustion – Weight loss – Weak grip strength – Slow walking speed – Low energy
expenditure















CHS, Cardiovascular Health Study; MCI, mild cognitive impairment; SCD, subjective cognitive decline; CDR,
Clinical Dementia Rating scale; IANA/IAGG, International Academy of Nutrition and Aging/International Asso-
ciation of Gerontology and Geriatrics.
different operational definitions of cognitive frailty,
but a lesser degree of heterogeneity was instead
observed for the definition of physical frailty, almost
exclusively operationalized by considering the CHS
criteria [7]. On the contrary, a relevant heterogene-
ity was observed with regard to the assessment of
cognitive functioning and the definition of cognitive
impairment. The panel of experts of the IANA-IAGG
suggested that all frail subjects should perform a com-
prehensive cognitive assessment exploring memory
performance as well as other cognitive functions, in
particular executive functions with Montreal Cog-
nitive Assessment test (MoCA), Mini-Mental State
Examination (MMSE), Alzheimer’s Disease Assess-
ment Scale-cognitive subscale (ADAS-Cog), and
speed processing tests to identify cognitive frailty
[35]. The objective was to exclude the diagnosis of
AD. However, the optimal measures or combination
of measures to accurately detect cognitive frailty in
the clinical setting are unclear [40], and in 2013,
the IANA-IAGG consensus described a hypothetical
condition without clinical findings available to sup-
port it. After four years of clinical research on this
novel construct, two very recent review articles inves-
tigated the body of evidence on the optimal measures
for detecting cognitive frailty in clinical populations
of older adults [41, 42]. In the first review, in the
49 identified studies, cognitive frailty was mainly
characterized by deficits in global cognitive func-
tion and was measured using cognitive screening
instruments such as the MMSE, the CDT, Mini-Cog
measures, or a series of cognitive tests (measur-
ing language, executive function, spatial ability, and
verbal and nonverbal memory) [41]. Additionally,
fifteen studies quantified cognitive frailty using self-
report of memory problems, and only three studies
included indicators to reflect specific aspects of
cognitive function, such as neuromotor processing,
verbal fluency, and executive function [41]. Another
integrative review, focused only on studies using the
IANA-IAGG cognitive frailty construct [35], iden-
tified eleven reports, of which two studies assessed
global cognition with the MMSE, four used the
MMSE and domain specific neuropsychiatric test-
ing, three used only domain neuropsychiatric testing,
and one assessed global cognition with both the
MMSE and MoCA with domain specific neuropsy-
chiatric testing [42]. While this review confirmed
the link between physical frailty and cognition with
developing validity to support distinct relationships
between components of physical frailty and cog-
nitive decline [42], inconsistencies in reporting of
reliability, validity, and heterogeneity in the mea-
surements and operational definition for cognitive
frailty suggested further research to establish a com-
monly accepted operational definition and develop
psychometrically appropriate clinical measures for
this novel clinical construct. Finally, recent findings
from the Multidomain Alzheimer Disease Preventive
Trial (MAPT) suggested that the cognitive profile of
cognitive frail individuals significantly differed from
individuals with cognitive impairment and without
physical frailty, scoring worse at executive and atten-
tion tests, and suggesting a pattern similar to that of
multiple-domain amnestic MCI [43]. Furthermore,
cognitive performance of subjects with 3 criteria or
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more of the frailty phenotype are cognitively more
impaired than subjects with only one [43].
Biomarkers of cognitive frailty
The IANA-IAGG consensus suggested some
biomarkers that may be able to capture both the risk of
future physical and cognitive declines, such as inflam-
matory markers [i.e., C-reactive protein (CRP) and
interleukin (IL)-6] [35]. A recent population-based
study with findings from the Italian Longitudinal
Study on Aging (ILSA) confirmed the role of inflam-
matory state in a model of potentially reversible
cognitive frailty that had a significant additional pre-
dictive effect on the risk of disability than the single
conditions of frailty or MCI in older individuals
without dementia and with elevated inflammation
[44]. However, biomarkers predictive of both types
of decline may not be particularly useful in differen-
tiating whether a person is at higher risk of a future
physical rather than a cognitive decline or vice versa
[35]. Other biomarkers may better serve at estimating
the specific risk for one single domain, i.e., markers
of amyloid- (A) accumulation and neurodegen-
eration or neuronal injury on which were mainly
based the National Institute on Aging–Alzheimer’s
Association (NIA-AA) research clinical criteria for
preclinical stages of AD [45] and MCI due to AD [46]
and the apolipoprotein E (APOE) ε4 genotype that is
closely related to the development of dementia and
AD [47]. According to the different types of cognitive
impairment, cognitive frailty was suggested to divide
into reversible and potentially reversible cognitive
frailty [19, 39]. The reversible cognitive impairment
may correspond to pre-MCI stage (CDR = 0) which
may be preclinical AD or other pre-MCI due to non-
AD with SCD. The potential reversible cognitive
impairment may correspond to MCI (CDR = 0.5), a
predementia state. Subjects with reversible cognitive
frailty and no biomarker evidence of AD pathology
could be individuals with normal cognitive aging or
undetectable preclinical AD [48]. Reversible cog-
nitive frail subjects with cerebral amyloidosis (A
accumulation on positron emission tomography amy-
loid imaging) could be individuals with preclinical
AD, early stage of dementia with Lewy bodies, or
VaD [48]. Reversible cognitive frail subjects with evi-
dence of neurodegeneration or neuronal injury plus
amyloidosis could be individuals with preclinical
AD, while without amyloidosis could be individuals
with normal cognitive aging or suspected non-AD
dementias [48]. Therefore, reversible cognitive and
functional damages as defined in these models of
cognitive frailty could be an optimal target for a
secondary prevention of cognitive and functional
impairment also for AD [36], hopefully including in




From 2013, date of the IANA-IAGG consensus
on cognitive frailty, and in the last two years only,
a relevant number of studies have proposed original
epidemiological findings strictly using the proposed
definition of this novel clinical construct on indi-
viduals in older age [43, 44, 49–55]. In particular,
there were three cross-sectional studies, and of these,
one report described the MAPT findings on the neu-
ropsychological profile of cognitive frail subjects
[43], the second evaluated the association of cogni-
tive frailty with functional independence [49], and
the third was specifically aimed at estimating the
prevalence of this condition [50]. Furthermore, five
longitudinal studies have explored the association
between cognitive frailty and adverse health-related
outcomes (mortality, hospitalization, quality of life,
and loss of functional independence) [44, 51, 54]
and cognitive-related outcomes such as progression
to dementia/neurocognitive disorders [44, 52–54].
Prevalence
The cumulative evidence coming from these first
eight studies estimating the prevalence of cognitive
frailty suggested a relevant heterogeneity with esti-
mates ranging from 1.0% to 22.0% [43, 44, 49–54]
(Table 2). A series of factors may contribute to this
wide variability, i.e., the different models of cognitive
frailty, the operationalization of the two components
of cognitive frailty (physical frailty and cognitive
impairment), the age and gender of the samples, and
the settings of the different studies. This last factor
appeared to be the strongest determinant of the dif-
ferent estimates, with clinical-based studies obtaining
higher prevalence of cognitive frailty (10.7%–22.0%)
[43, 52] compared with population-based studies
(ranging from 1.0% to 4.4%) [44, 49, 50, 52–54].
With regard to age and gender, in population-based
settings, findings on 1575 older subjects from the
Singapore Longitudinal Ageing Studies (SLAS), sug-
gested that the prevalence of a potentially reversible
cognitive frailty model (coexisting physical frailty
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Table 2
Principal clinical- and population-based studies estimating the prevalence of different models of cognitive frailty
Reference Study design and Sample, Age, Operationalization of cognitive frailty Prevalence, %
setting n mean ± SD
Cross-sectional studies




1,617 75.4 ± 4.5 Potentially reversible cognitive frailty defined
with the presence of physical frailty
operationalized with the modified CHS
criteria (≥1 criterion) and cognition assessed
using a CDR of 0.5, and absence of concurrent











8,864 73.4 ± 0.3 Potentially reversible cognitive frailty defined
with the presence of physical frailty
operationalized with the modified CHS
criteria (>3 criteria) and cognition assessed
using the National Center for Geriatrics and
Gerontology-Functional Assessment Tool, and








594 73.6 ± 5.8 Potentially reversible cognitive frailty defined
with the presence of physical frailty
operationalized with the modified CHS
criteria (>1 criterion) and cognition assessed
using a score < 25 on the MMSE. Not





et al., 2016 [52]
Longitudinal clinical-based
study with 5 years of
follow-up; the Gait and Brain
Study
255 73.6 ± 8.6 Potentially reversible cognitive frailty was
defined with the presence of physical frailty
operationalized with the modified CHS
criteria (≥3 criteria) and cognition assessed
using the MoCA score below 26 and a CDR of
0.5, and absence of concurrent dementia. Gait
was assessed using an electronic walkway
10.7
Feng et al., [53] Longitudinal population-based
study with 3 years of
follow-up; the Singapore
Longitudinal Ageing Studies
1575 66.0 ± 7.6 Potentially reversible cognitive frailty was
defined with the presence of physical frailty
operationalized with the modified CHS
criteria (≥3 criteria) and cognition assessed
with the Chinese version MMSE, and absence
of concurrent dementia
1.0
Feng et al., [51] Longitudinal population-based
study with 3 years of
follow-up; the Singapore
Longitudinal Ageing Studies
2375 65.8 ± 7.5 Potentially reversible cognitive frailty was
defined with the presence of physical frailty
operationalized with the modified CHS
criteria (≥3 criteria) and cognition assessed






study with 3.5 years of
median follow-up; the Italian
Longitudinal Study on Aging
2373 76.7 ± 4.4 Potentially reversible cognitive frailty was
defined with the presence of physical frailty
with a modified phenotype operationalized
with the modified CHS criteria (≥3 criteria),
MCI diagnosed with modified Petersen





study with 3.5 and 7 years of
median follow-up; the Italian
Longitudinal Study on Aging
2150 73.2 ± 5.6 Reversible cognitive frailty was defined with the
presence of physical frailty with a modified
phenotype operationalized with the modified
CHS criteria (≥3 criteria), pre-MCI SCD,
diagnosed with a self-report measure based on
item 14 of the 30-item GDS, and absence of
concurrent dementia
2.5
CHS, Cardiovascular Health Study; CDR, Clinical Dementia Rating scale; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental
State Examination; pre-MCI SCD, pre-mild cognitive impairment subjective cognitive decline; GDS, Geriatric Depression Scale.
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and cognitive impairment operationalized with a
score < 23 on the Chinese version of the MMSE)
was 1% [95% confidence interval (CI): 0.5–1.4] but
was higher among participants aged 75 and older
(5.0%; 95% CI:1.8–8.1) [53], although, the preva-
lence increased to 1.8% when estimated on 2375
older individuals from the SLAS [51]. These data
were confirmed from the ILSA, in which the preva-
lence of potentially reversible cognitive frailty was
1.0, increasing with class of age, and more repre-
sented (about twice) in women than in men [44].
Other Japanese findings from the National Center for
Geriatrics and Gerontology–Study of Geriatric Syn-
dromes database confirmed a prevalence rate of 1.2%
of a potentially reversible cognitive frailty model
[49]. However, in 594 Italian community-dwelling
older adults, the prevalence rate of a potentially
reversible cognitive frailty model (physical frailty
and cognitive impairment operationalized with a
score < 25 on the MMSE) was 4.4%, and this higher
estimate may be explained by the general higher
age in this sample [50]. With regard to the cogni-
tive frailty model used, in population based settings,
almost all the studies reviewed adopted a model of
potentially reversible cognitive frailty [44, 49–51,
53], while, at the best of our knowledge, only one
large population-based study estimated a model of
reversible cognitive frailty (physical frailty plus pre-
MCI SCD) with findings from the ILSA (prevalence:
2.5%) [54]. Furthermore, the operationalization of
physical frailty could influence the prevalence esti-
mates. In fact, a single study adopted at least one CHS
criterion for diagnosing physical frailty, so consider-
ing as frail also prefrail older subjects, and reporting
higher prevalence (prevalence: 22.0%) [43], while the
remaining studies only slightly modified the orig-
inal CHS criteria [43, 44, 49–54]. Finally, higher
estimates were also obtained in another study not
excluding subjects with dementia or other concomi-
tant neurodegenerative conditions (prevalence: 4.4%)
[50].
Cognitive frailty and adverse health-related
outcomes
Some cross-sectional and longitudinal population-
based studies investigated different cognitive frailty
models associated with functional disability, quality
of life, hospitalization, and all-cause mortality [44,
49–51, 54] (Table 3), health-related outcomes tradi-
tionally linked to different frailty models. Recently,
two cross-sectional population-based studies found
in individuals with potentially reversible cognitive
frailty a higher risk of instrumental activities of
daily living limitation (National Center for Geriatrics
and Gerontology–Study of Geriatric Syndromes
database) [49] and disability [50]. Very recently, data
from the ILSA suggested that in older individuals
with potentially reversible cognitive frailty and a
high level of inflammation, a significant additional
predictive effect only on the risk of disability has
been found, but not of all-cause mortality [44]. In
the same study, over 3.5-year and 7-year follow-
ups, older individuals with reversible cognitive frailty
showed an increased risk of all-cause mortality [haz-
ard ratio (HR): 1.74, 95% CI: 1.07–2.83 and HR:
1.39, 95% CI 1.03–2.00, respectively] [54]. These
apparently discrepant findings suggested a different
impact of different models of cognitive frailty on the
risk of all-cause mortality. Longitudinal data from
the SLAS showed that potentially reversible cogni-
tive frailty was associated with an evidently high risk
of functional disability, poor quality of life, and mor-
tality, but not of hospitalization [51], giving further
support to the previous findings of an impact of cog-
nitive frailty on adverse health-related outcomes in
population-base settings.
Cognitive frailty and cognitive-related outcomes
Four longitudinal population-based studies inves-
tigated different cognitive frailty models associated
with incidence of dementia, AD, VaD, and neu-
rocognitive disorders [44, 52–54] (Table 4). In the
Singapore Longitudinal Ageing Studies (SLAS),
continuous physical frailty score and MMSE score
showed significant individual and joint associations
with incident mild and major neurocognitive disorder
[53]. In this study, potentially reversible cogni-
tive frailty conferred additionally greater risk of
incident neurocognitive disorder (mild plus major
neurocognitive disorder) [53]. Moreover, very recent
findings from the Gait and Brain Study suggested
that another model of potentially reversible cognitive
frailty (physical frailty plus CDR of 0.5) increased
incident rate but not risk for progression to dementia,
although, the combination of slow gait and objec-
tive cognitive impairment, which has been labeled
as the Motoric Cognitive Risk syndrome [55], posed
the highest risk for progression to dementia when
compared with physical frailty and cognitive frailty
models [52]. Possible discrepancies in predicting
cognitive-related outcomes may arise from different
models of cognitive frailty in which cognitive impair-
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Table 3
Principal cross-sectional and longitudinal population-based studies on the association of different cognitive frailty models with adverse
health-related outcomes










IADL status (use of public
transportation, shopping, management
of finances, and housekeeping)
Significant relationships between
IADL limitations and physical
frailty (OR: 1.24, 95% CI: 1.01 to
1.52), cognitive impairment (OR:
1.71, 95% CI: 1.39 to 2.11), and
potentially reversible cognitive






Disability measured with the Groningen
Activity Restriction Scale
Individuals with potentially
reversible cognitive frailty showed
a higher disability level in






study with 3 years of
follow-up; the Singapore
Longitudinal Ageing Studies
Functional disability assessed by
self-reported measures of IADL and
ADL. QOL measured using the
Medical Outcomes Study SF-12
physical component summary (PCS)
of QOL. Hospitalization and mortality
Individuals with potentially
reversible cognitive frailty stood
out with 12- to 13-fold increased
prevalence and incidence of
functional disability, a five- and
27-fold increased prevalence and
incidence of low QOL, and a
fivefold increased mortality risk.
Regarding hospitalization, in
cross-sectional and longitudinal
analyses, no association across
subcategories of physical frailty





study with 3.5 years of median
follow-up; the Italian
Longitudinal Study on Aging
Disability measured with ADL and
all-cause mortality
In potentially reversible cognitively
frail older individuals with a high
inflammatory state has been found
a significant additional predictive
effect on the risk of disability than
in frail/non-MCI individuals, while
it has not been found for all-cause
mortality. In the potentially
reversible cognitive frailty and
high inflammatory state group, the
predicted number of older subjects
disabled was about 461 per





study with 3.5 and 7 years of
median follow-up; the Italian
Longitudinal Study on Aging
All-cause mortality Over 3.5-year and 7-year follow-ups,
participants with reversible
cognitive frailty showed an
increased risk of all-cause
mortality (HR: 1.74, 95% CI:
1.07–2.83 and HR: 1.39, 95% CI
1.03–2.00, respectively). Vascular
risk factors and depressive
symptoms did not have any effect
modifier on the relationship
between reversible cognitive frailty
and all-cause mortality
IADL, instrumental activities of daily living; ADL, activities of daily living; QOL, quality of life; OR, odds ratio; CI, confidence interval;
HR, hazard ratio.
1002 F. Panza et al. / Cognitive Frailty and Prevention of Dementia
Table 4
Principal longitudinal population-based studies on the association of different cognitive frailty models with late-life cognitive decline,
dementia, Alzheimer’s disease (AD), vascular dementia (VaD) and other cognitive-related outcomes





with 5 years of follow-up; the Gait
and Brain Study
Cognitive decline operationalized as
a decrease of at least two points in
MoCA scores between baseline
and the last assessment, incidence
of dementia according to DSM-IV
criteria and when CDR progressed
to one or higher
The combination of slow gait and
objective cognitive impairment
posed the highest risk for
progression to dementia (HR: 35.9,
95% CI: 4.0–319.2) when
compared with physical frailty and
potentially cognitive frailty models
Feng et al., [53] Longitudinal population-based study
with 3 years of follow-up; the
Singapore Longitudinal Ageing
Studies
Incidence of neurocognitive disorder
according to DSM-5 criteria
Continuous physical frailty score and
MMSE score showed significant
individual and joint associations




greater risk of incident
neurocognitive disorder (mild plus
major neurocognitive disorder)
Solfrizzi et al., [44] Longitudinal population-based study
with 3.5 years of median
follow-up; 1575 older individuals
from the ILSA
Incidence of dementia diagnosed
with the DSM-III-R, AD diagnosed
with the NINCDS-ADRDA
criteria, VaD diagnosed with the
NINDS-AIREN criteria
These findings did not support a
predictive role of a potentially
reversible cognitive frailty model
for the development of incident
dementia compared with physical
frailty or MCI alone
Solfrizzi et al., [54] Longitudinal population-based study
with 3.5 and 7 years of median
follow-up; 2150 older individuals
from the ILSA
Incidence of dementia diagnosed
with the DSM-III-R, AD diagnosed
with the NINCDS-ADRDA
criteria, VaD diagnosed with the
NINDS-AIREN criteria
Over a 3.5-year follow-up,
participants with reversible
cognitive frailty showed an
increased risk of overall dementia
(HR: 2.30, 95% CI: 1.02–5.18],
particularly VaD (HR: 6.67, 95%
CI 2.11–20.99). Over a 7-year
follow-up, participants with
reversible cognitive frailty showed
an increased risk of overall
dementia (HR: 2.12, 95% CI:
1.12–4.03), particularly VaD (HR:
6.85, 95% CI (3.16–14.83).
Vascular risk factors and depressive
symptoms did not have any effect
modifier on the relationship
between reversible cognitive frailty
and incident dementia
MoCA = Montreal Cognitive Assessment; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders-IV; CDR, Clinical Dementia
Rating scale; HR, hazard ratio; CI, confidence interval; DSM-5, Diagnostic and Statistical Manual of Mental Disorders-5; MMSE, Mini-
Mental State Examination; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders-III revised; NINCDS-ADRDA, National
Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association; NINDS-AIREN,
National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences;
MCI, mild cognitive impairment.
ment may be operationalized in different ways. In
fact, findings from the ILSA did not support a pre-
dictive role of a potentially reversible cognitive frailty
model (physical frailty plus MCI) for the develop-
ment of incident dementia compared with physical
frailty or MCI alone [44]. However, other findings
coming from the ILSA suggested that a model of
reversible cognitive frailty (physical frailty plus pre-
MCI SCD) was a short- and long-term predictor of
overall dementia, particularly VaD [54]. In observa-
tional studies like the ILSA, in extreme cases, could
be of interest to verify that an interaction may reverse
the relationship between the risk factor and the out-
come. Therefore, it was hypothesized that the role
of vascular factors and/or depressive symptoms as
effect modifiers could change the risk of demen-
tia and all-cause mortality linked to the presence
of reversible cognitive frailty. In particular, trying
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to support the reversibility of this new clinical con-
struct, it was focused on the group of people without
these risk factors as a proxy of optimal manage-
ment of these factors. In the ILSA, the absence of
vascular risk factors and depressive symptoms did
not modify the predictive role of reversible cogni-
tive frailty on these outcomes [54]. Probably, the
identification of reversibility due to several possi-
ble interventions could be possible designing specific





From a pathophysiological point of view, the eti-
ology of the cognitive-frailty association appeared
to be multifactorial and several mediators or possi-
ble pathways have been suggested to explain these
links and hormonal and inflammatory processes,
together with nutritional, vascular, neuropatholog-
ical, and metabolic influences may be of major
relevance [19, 29, 37, 39, 40, 56–58]. However, given
that experimental evidence is lacking, other ques-
tions may address the underlying mechanisms and
determine which is the most relevant component
among the suggested mediators between frailty and
cognition. The common consequences of aging may
have an impact on age-related conditions such as
physical frailty and cognitive decline. The common
aging mechanisms, such as nutrition sensing signals,
p53 activation, and subsequent telomere deletion and
DNA damage, result in the physiological reserve
declines of different organs. The long-term chronic
stressor overload further accelerates the physiolog-
ical reserve declines. The different vulnerability of
multiple organs, or different structures in same organ,
such as brain, results in function-related homeostatic
failure, and different phenotypes/diseases, physical
frailty, or cognitive frailty [19, 59]. These different
mechanisms are not mutually exclusive, highlight-
ing the need for further studies to better explicate the
neurobiological basis of cognitive frailty.
Vascular risk factors and diseases
The contribution of cardiovascular dysfunction
(congestive heart failure, myocardial infarction,
peripheral arterial diseases, diabetes mellitus, and
hypertension) to cognitive frailty in older adults is
uncertain. Cardiovascular risk factors and common
vascular diseases have been related to both frailty
and cognitive impairment [34]. Physical frailty may
be a prodromal stage of VaD [60, 61] and was
clearly related to subclinical vascular biomarkers
and higher degree of infarct-like lesions in the
brain [62]. Furthermore, the suggested association
between physical frailty and increased risk of inci-
dent AD [38] may be explained by the underlying
increased risk of stroke and cerebrovascular disease.
The lesions most evidently linking cognitive decline
with frailty are leukoaraiosis [white matter hyper-
intensities (WMHs)] reflecting chronic blood flow
reduction [63]. WMH are frequently associated with
vascular disease (i.e., hypertension, diabetes, smok-
ing, and cardiovascular disease). Abnormalities of
cardiac structure and function may be independently
associated with frailty, showing the greatest associa-
tion with frailty among several other organ systems,
i.e., vascular, pulmonary, renal, hematologic, and adi-
pose systems [64]. Conversely, the findings from
the ILSA suggested that the association between
reversible cognitive frailty and VaD persisted in anal-
yses after controlling for vascular risk factors and
diseases [54]. Probably, the identification and inter-
vention on vascular risk factors should be done earlier
to estimate a positive effect on still unclear possible
reverse processes.
Sarcopenia
Biomarkers of physical frailty, particularly sar-
copenia, should predict early cognitive decline.
Sarcopenia, an age-related decline in skeletal mus-
cle mass and muscle function [65, 66] and a reliable
marker of frailty, may be accelerated by some comor-
bid conditions including vascular diseases such as
congestive heart failure and peripheral arterial dis-
eases [67]. Sarcopenia could worsen the prognosis
of many diseases, including AD [68], and a link
also exists between sarcopenia-related declines and
cognition [69]. Sarcopenia, which produces muscle
dysfunction, slow gait velocity and cognitive decline,
could share a strong bidirectional relationship, and
this suggests the coexistence of both cognitive and
motor dysfunctions in older persons to characterize
the recently proposed MRC, a syndrome character-
ized by slow gait and cognitive complaints [70].
Metabolic factors
Findings from the I-Lan Longitudinal Aging Study
(ILAS) identified three distinct subtypes of the phys-
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ical frailty phenotype: non-mobility subtype (weight
loss and exhaustion), mobility subtype (slowness
and weakness), and physically inactive subtype (low
psychical activity) [71]. In the ILAS, compared to
robust subjects, people in the non-mobility subtype
had poorer bone health and more metabolic serum
abnormalities [71]. In particular, in contrast to the
muscle catabolic or neurological pathway leading to
the mobility subtype, the underlying mechanism of
non-mobility subtype may be even more complicated.
Interestingly, subjects in the non-mobility subtype
had some metabolism-related declines, including
poor nutrition status, higher glycated hemoglobin,
higher low-density lipoprotein cholesterol, and lower
high-density lipoprotein cholesterol serum levels,
and they were also the most depressed group over-
all [71]. Metabolic conditions may be associated
with physical frailty independently of sarcopenia
[72] and cognitive impairment in older subjects [73].
For example, inappropriate secretion of insulin in
response to increased levels of plasma glucose due to
insulin resistance results in hyperinsulinemia, which
leads to the exposure of cells to high levels of insulin
for a long period of time. This situation adversely
affects the function and survival of cells, especially
neurons [74]. For research purposes, the “metabolic-
cognitive syndrome” has been proposed as a model of
cognitive impairment linked to metabolic syndrome
and metabolic disorders in patients with metabolic
syndrome plus cognitive impairment of degenerative
or vascular origin [75], that could underlie also frailty
in older age [76]. In recent years, a plausible mecha-
nism intensively investigated is the accumulation and
activation of macrophages in adipose tissue, which
may trigger low-grade chronic systemic and neuroin-
flammation through the release of proinflammatory
cytokines [i.e., tumor necrosis factor (TNF), IL-1b,
IL-6] [77]. Increased plasma levels of cytokines have
been associated with an increased risk of demen-
tia [78]. Dietary saturated fats induce inflammatory
responses on microglia, leading to local cytokine pro-
duction, involving often hypothalamic nuclear factor
kappa B activation, which may lead to apoptosis of
key neurons involved in body weight control, central
regulation of energy balance, glucose homeostasis,
and blood pressure [79].
Nutritional factors
Oxidative stress, low-grade systemic inflamma-
tion, neuroinflammation, and altered autophagy, all
associated with obesity, metabolic syndrome, and
insulin resistance, are proposed mechanisms to
explain the influence of nutrition on cognitive health
[80], and current epidemiological evidence suggested
that diet-related factors may be also associated with
late-life cognitive disorders [81, 82]. Older subjects
with protein energy undernutrition, a treatable condi-
tion, have poorer cognitive performance [83]. Weight
loss, reduced caloric intake, and the reduced intake
of specific nutrients are associated with detectable
changes in body composition and physical function
characterizing the transition from independence to
disability in older age [84], with weight loss also
proposed as a dementia risk factor [85]. Numerous
dietary components and supplements with poten-
tial antioxidant, anti-inflammatory, and vasodilating
actions have been investigated on their effects on
cognitive decline. This includes vitamins (e.g., beta-
carotene, folic acid, vitamin B6 and B12, vitamins
C, D, and E), minerals (e.g., zinc and magnesium),
n-3 polyunsaturated fatty acids, and other com-
pounds and supplements (e.g., curcumoids, gingko
biloba, acetyl-L-carnitine, phytoestrogens, tea and
()-epigallocatechin-3-gallate, resveratrol, garlic, and
caffeine) [80]. Adherence to the Mediterranean diet
is also associated with slower cognitive decline,
reduced risk of AD and progression from MCI to AD,
and decreased mortality in AD patients [72, 16, 86,
87], confirming the interplay among dietary patterns,
frailty, and cognition.
The anorexia of aging, one of the modern geri-
atric giants, is defined as age-related reduction in
appetite and food intake, which occurs even in
illness-free adults and in the presence of adequate
food supply, resulting from physiological, patho-
logical, and social factors [88]. Loss of appetite
may lead to protein-energy malnutrition and weight
loss, with numerous poor health outcomes [89],
including increased mortality. In the elderly, weight
loss is associated with impaired muscle function,
falls, decreased bone mass, immune dysfunctions,
anemia, pressure ulcers, reduced cognitive func-
tions, poor wound healing, delayed recovery from
surgery, functional decline, and increased morbid-
ity and mortality [90]. The decrease in food intake
associated with anorexia leads to the frailty syn-
drome [91]. The etiology of the anorexia of aging
is multi-factorial and includes a combination of
physiological changes associated with aging (decline
in smell and taste, reduced central and peripheral
drive to eat, delayed gastric emptying), patho-
logical conditions (depression, dementia, somatic
diseases, medications and iatrogenic interventions,
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oral-health status), and social factors (poverty,
loneliness) [92].
Hormonal factors
Once again, sarcopenia may explain the cognitive-
frailty link given its association with the development
of frailty and cognitive impairment, also through its
association with low serum levels of testosterone in
men [93]. In fact, reduced testosterone and other
androgen hormones may be involved in the devel-
opment of frailty and cognitive decline. Testosterone
may promote hippocampal synaptic plasticity and
regulate amyloid deposition [94], while age-related
depletion of testosterone may be associated with
frailty by reducing muscle mass and strength [95].
Moreover, during aging, a reduction in sex steroids,
growth hormone, and vitamin D levels are associ-
ated with increased baseline levels of inflammatory
proteins [96]. Increased basal cortisol levels have
a role in cognitive decline and might be associ-
ated with decreased hippocampal volume in patients
with Cushing syndrome, depression, and AD [97].
Higher levels of cortisol were associated with worse
performance in six cognitive domains (language,
processing speed, eye-hand coordination, executive
functioning, verbal memory and learning, and visual
memory) in adults aged 50 to 70 years, suggesting that
dysregulation of the hypothalamic-pituitary adrenal
axis (HPA) could be a risk factor for poorer cognitive
function in older people [97]. Reduced ghrelin secre-
tion might also contribute to the metabolic changes
observed in male patients with AD [98]. Ghrelin
has been linked to neuromodulation, neuroprotection,
memory, and learning processes due to its expression
in different regions of the central nervous system [98].
Inflammatory factors
Findings from the ILSA suggested that a signif-
icant difference in disability rates existed between
the MCI and non-MCI groups in frail individuals
with high inflammation. Therefore, with inflamma-
tion, a potentially reversible cognitive frailty model
may have an additional predictive effect on the dis-
ability risk than frailty or MCI alone [44]. In frailty,
increased markers of inflammation such as CRP or
proinflammatory ILs are common [99], with chronic
inflammation implicated in the frailty process [100]
and also in cognitive impairment and dementia [101].
The possible link among chronic inflammation, phys-
ical frailty, and cognition was directly confirmed by
some studies [102]. In fact, higher IL-6 and CRP iden-
tified one of the subdimensions of the CHS model
of physical frailty with elevated predictive validity
for mortality [103]. Furthermore, circulating levels
of CRP mediated the relationship between muscle
strength and poor cognitive function, but only in
women [104]. Chronic inflammation is also impli-
cated in a series of possible mediators of the link
between physical frailty and cognition such as hor-
monal dysregulation, oxidative stress, cardiovascular
disease, and social isolation [29, 105].
Psychosocial factors
One psychological factor that may influence the
risk of becoming frail in later life is personality, a
largely stable set of traits and characteristics that
influence behavior, thoughts, and feelings. People
who are higher in conscientiousness also have a
reduced risk of dying from cardiovascular disease
[106], cognitive decline [107], and dementia [108].
On the contrary, people who are higher in neuroti-
cism, the tendency to experience negative emotion,
may have an increased risk of cognitive decline [107]
and dementia [108]. In a prospective study of people
aged 60 to over 90 years, higher levels of neuroticism
and lower levels of extraversion and conscientious-
ness were associated with greater frailty at follow-up
around 2 years later [109]. There is evidence that
personality may be associated with individual dif-
ferences in physiological processes that have been
hypothesized to underlie the onset of frailty, namely
inflammation and the HPA dysregulation [110, 111].
Depression is both a risk factor for and a con-
sequence of frailty. Depression is also known to
affect cognitive function [112], suggesting that one
mechanism underlying the link between frailty and
cognition may be owing to psychological factors
such as mood disorders. Moreover, the Health and
Retirement Survey showed that participants with vas-
cular depression at baseline were at increased risk
of developing frailty [113], suggesting that the inter-
play between depression and vascular burden may
underlie the frailty-cognition link. Finally, depres-
sion, especially in the older age group, is often
associated to a loss of social networks. In particular,
epidemiological [114] and neuropathological [115]
evidence suggested that social isolation and loneli-
ness, known contributors to physical frailty [116],
may lead to cognitive decline and AD, with limited
physical activity further reduced by social isolation
[105].
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DISCUSSION
Cognitive frailty is a condition recently defined by
operationalized criteria describing the contemporary
presence of physical frailty and MCI. Two subtypes
for this clinical construct have been proposed: poten-
tially reversible cognitive frailty (physical frailty
plus MCI) and reversible cognitive frailty (physical
frailty plus pre-MCI subjective cognitive decline).
In the last two years, several reports have proposed
original epidemiological findings strictly using the
proposed definition of this novel clinical construct
on individuals in older age. These studies suggested
a relevant heterogeneity with prevalence estimates
ranging from 1.0% to 22.0%, in particular, from 10.7
to 22% in clinical-based settings and from 1.0 to 4.4%
in population-based settings. Cross-sectional and lon-
gitudinal population-based studies suggested that
different cognitive frailty models may be associated
with increased risk of functional disability, worsened
quality of life, hospitalization, and all-cause mortal-
ity. Some large longitudinal population-based studies
showed that different cognitive frailty models may
increase the risk of incidence of dementia, VaD, and
neurocognitive disorders.
Preventive strategies for cognitive frailty
In older subjects, at community level, primary pre-
ventive intervention to delay onset of frailty includes
the promotion of physical activities, exercise and a
healthy diet, the cessation of smoking, engaging in
an active and socially integrated lifestyle, the main-
tenance of a proper body weight, and metabolic and
vascular risk control, including dyslipidemia, dia-
betes, and blood pressure [117]. Physical frailty and
cognitive frailty are two phenotypes of frailty that are
becoming possible secondary prevention targets in
early/asymptomatic dementia stage [36]. Cognitive
frailty, a clinical construct reassembling cognitive
impairment associated to its possible physical causes,
has a potential for reversibility. Of course, at this
stage, the prevention of cognitive frailty progression
towards overt dementia is only a striking hypothe-
sis. However, fulfilling the compression of morbidity
hypothesis originally proposed by Fries, in which the
burden of lifetime disease may be compressed into a
shorter period before the time of death, if the age of
onset of the first chronic infirmity can be postponed
[118], the prevention of cognitive frailty progression
may increase survival also in the very old with cog-
nitive impairment deriving from physical causes or
at least their quality of life and functional indepen-
dence [119]. For different models of cognitive frailty,
physical frailty should precede the onset of cogni-
tive impairment [120], thus, intervention programs
targeted to improve frailty may prevent also late-
life cognitive disorders. An understanding of best
clinical management strategies targeting frailty in
multiple settings is evolving. Convincing evidence
from high-quality studies is lacking [121, 122], how-
ever, new systematic reviews are underway [123,
124]. Physical activity and nutrition are the overarch-
ing interventions for prevention and management of
frailty [80, 125, 126]. Systematic reviews supported
the value of exercise interventions in decreasing falls
and improving gait ability [125, 126], while there was
only preliminary evidence coming from RCTs that
nutrition could postpone frailty in older age [127].
A healthy dietary pattern, namely the Mediterranean
diet, has shown to positively affect both physical and
cognitive frailty [29, 80, 128]. The Finnish Geriatric
Intervention Study to Prevent Cognitive Impairment
and Disability (FINGER) study showed that a mul-
tidomain intervention combining Mediterranean diet,
exercise, and brain stimulation slowed cognitive loss
in older adults [129]. Nutrition itself may be con-
sidered a multidomain intervention due to its ability
to deliver benefit at biological, clinical, and social
levels [80]. A very recent systematic review showed
that multidomain interventions tended to be more
effective than monodomain interventions on frailty
status or score, muscle mass and strength, and phys-
ical functioning, while findings were inconclusive
for cognitive, functional, and social outcomes [130].
Physical exercise seems to play an essential role
in the multidomain intervention, whereby additional
interventions can lead to further improvement (i.e.,
nutritional intervention) [130]. At this stage of clini-
cal development of the construct of cognitive frailty,
secondary preventive strategies for cognitive impair-
ment and physical frailty may be suggested. For older
subjects with cognitive frailty, particularly reversible
cognitive frailty, secondary prevention is required,
with a CGA determining the cause of cognitive frailty
and an evidence-based and individualized multido-
main interventions similar to that of the FINGER
[129]. Other measures, such as drug treatment for
chronic diseases, fall prevention, and exercise and
nutrition support, which target physical, nutritional,
cognitive, and psychological domains, may delay the
progression to overt dementia and secondary occur-
rence of adverse health-related outcomes, such as
disability, hospitalization, and mortality [49, 117].
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Although evidence on interventions in cognitive frail
subjects is limited, a small number of studies point
to the cognitive benefits of physical activity and
nutrition. In fact, physical activity protected against
both sarcopenia and cognitive decline in experimen-
tal training trials and in observational studies [131].
Furthermore, findings from recent preventive RCTs
suggested that physical exercise training in combi-
nation with protein supplementation [132] or alone
[133] improved also cognitive outcomes in frail and
pre-frail states, opening new viable routes for the pre-
vention of cognitive and functional decline in these
patients.
Controversies and future directions
A recent expert consensus panel of the IAGG
and its Global Aging Research Network (GARN)
agreed that persons with cognitive decline should be
screened for physical frailty and vice versa [128],
although the IAGG-GARN panelists agreed that more
studies on the interaction of the two entities and
their pathophysiology are needed [128]. In fact, also
open and unresolved issues exist in the field and
the concept of cognitive frailty has still significant
limitations for its broad implementation in clinical
practice. A robust operational definition of its indi-
vidual components (i.e., physical frailty and cognitive
impairment) and characterization of the clinical and
biological mediators are still lacking [128, 134, 135],
although, in the last two years, a growing body of epi-
demiological evidence suggested preliminary clinical
validation for this clinical construct [43, 44, 49–54].
No universal criteria or consensus operational def-
inition has been reached for frailty, and therefore
also for its phenotypes, including cognitive frailty.
However, the current working definitions of cognitive
frailty [20, 34, 38] may provide a valuable starting
point for the development of a coherent and largely
accepted operational definition. Notwithstanding, we
need different operational definitions for its indi-
vidual components. While the physical factors of
cognitive frailty were diagnosed with the physical
frailty model operationalized with the CHS crite-
ria, the cognitive pattern of this clinical construct
was not clearly characterized. In the epidemiologi-
cal section of the present review, we did not include
some studies estimating the prevalence of cognitive
frailty and using frailty indexes based deficit accu-
mulation model to operationalize frailty [136, 137].
Of course, frailty indexes were investigated in studies
associating frailty to late-life cognitive disorders [39],
in particular, the nontraditional risk factors index
(Frailty Index-NTRF) that was developed using a
series of 19 deficits not known to predict dementia
and AD [139]. Furthermore, very recently, findings
from the Toledo Study for Healthy Aging Cogni-
tive suggested that cognitive performance was worse
with a worse degree of frailty, independently of the
model used (physical frailty, frailty indexes, or the
Frailty Trait Scale, a new muldimensional measure of
frailty) [139]. However, the studies published so far
using the IANA/IAGG criteria adopted the definition
of physical frailty almost exclusively operationalized
by considering the CHS criteria [7]. Furthermore,
given the potential for reversibility of the cognitive
frailty construct, physical frailty identifies a primary
or pre-clinical frailty state [15], i.e., a potential tar-
get for prevention. On the contrary, frailty indexes
identify secondary or clinical frailty [15], associated
with known comorbidities and/or disability, a condi-
tion that can be unlikely reversed. However, cognitive
frailty is not an uncontroversial term. In fact, a motor
signature that preceded cognitive decline and which
has been labeled as the Motoric Cognitive Risk syn-
drome, the combination of slow gait and objective
cognitive impairment, further casted doubt on the
empirical basis of the cognitive frailty syndrome [55].
For the cognitive impairment component, although
the relevant heterogeneity observed in recent sys-
tematic reviews [41, 42], epidemiological findings
suggested that the ability of different cognitive frailty
models in predicting cognitive-related outcomes may
arise from the different ways in which cognitive
impairment may be operationalized [44, 54]. In fact,
while a potentially reversible cognitive frailty model
(physical frailty plus MCI) had no predictive role
for the development of incident dementia compared
with physical frailty or MCI alone [44], a model
of reversible cognitive frailty (physical frailty plus
pre-MCI SCD) was a short- and long-term predictor
of overall dementia, particularly VaD [54], suggest-
ing that subjective cognitive disturbances may be
central for the definition of cognitive impairment
in cognitive frailty. The early detection of cognitive
disturbances at a subjective level may be a promis-
ing focus for the development of preventive and
therapeutic interventions. Finally, none of the avail-
able studies on cognitive frailty explicitly addressed
the relationship between physical frailty and cogni-
tive impairment within the cognitive frailty construct
[135], identifying conditions characterized by the co-
occurrence of physical and cognitive decline, without
clarifying their relationship. A causal, or at least,
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temporal criterion could be crucial to increase the
possibility of detecting cognitive disturbances related
to physical causes, so representing a single com-
plex phenotype, as suggested by the cognitive frailty
construct [39]. Alternatively, physical frailty and
cognitive impairment could be two different conse-
quences of a common underlying mechanism (i.e.,
vascular diseases or neurodegeneration) or represent-
ing two separate and coexisting conditions occurring
in older age. In conclusion, reversible cognitive and
functional damages as defined in these models of
cognitive frailty could be an optimal target for a
secondary prevention of cognitive and functional
impairment also for early/asymptomatic dementia
stage. The operationalization of clinical constructs
based on cognitive impairment related to physical
causes (physical frailty, motor function decline, or
other physical factors) appears to be interesting for
dementia secondary prevention given the increased
risk for progression to dementia of these clinical enti-
ties. In the near future, the present consensual criteria
for cognitive frailty should be redefined, with the use
of different operational definitions for frailty and cog-
nitive impairment, and useful clinical, biological, and
imaging markers to develop a better understanding of
the bidirectional relationship of these conditions, pre-
venting late-life cognitive disorders with intervention
programs targeted to improve frailty.
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